Neurocrine Biosciences, Inc.
NBIX
Market Cap$12.52B
Close$
$350.98
173.8% upside
Current Fair Value
173.8% upsideUndervalued by 173.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.52 Billion |
|---|---|
| Enterprise Value | $12.78 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $3.4 |
| Beta | 0.24 |
| Outstanding Shares | 99,700,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 41.26 |
|---|---|
| PEG | -50.44 |
| Price to Sales | 5.34 |
| Price to Book Ratio | 5.13 |
| Enterprise Value to Revenue | 5.3 |
| Enterprise Value to EBIT | 25.67 |
| Enterprise Value to Net Income | 41 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Neurocrine Biosciences, Inc.
CEO: Kevin Gorman